Universal reference book for medicines
Product name: KANGLAYT (KANGLAITE)

Active substance: nonappropriate

Type: Antitumor preparation

Manufacturer: ZHEJIANG KANGLAITE PHARMACEUTICAL (China)
Composition, form of production and packaging
Emulsion for
white infusions such as oil in water.

1 ml of 1 fl.
(100 ml)
oil of coix seeds 100 mg 10 g

Auxiliary substances: lecithin soy, glycerol, water d / u.

100 ml - bottles (1) - packs of cardboard.

INSTRUCTION FOR THE SPECIALIST.

The description of the drug was approved by the manufacturer for the 2006 print edition.

PHARMACHOLOGIC EFFECT

Antitumor drug.
The mechanism of action is due to the inhibition of mitosis of tumor cells, the induction of their apoptosis and the effect on the expression of tumor cells.
INDICATIONS

non-small cell lung cancer.

DOSING MODE

The drug is administered as a slow intravenous infusion in a dose of 20 g (200 ml) daily for 21 days.
The break between the course of treatment should be 3-5 days.The treatment cycle includes 2 courses.
When a combination of the drug with chemotherapy or radiation therapy, the dose of KLT can be reduced.

At the beginning of intravenous administration, it is recommended to set the infusion rate at the level of 20 drops / min for the first 10 minutes, after 20 minutes the rate can be gradually increased to 40-60 drops / min (after 30 minutes from the start of the injection).

SIDE EFFECT

Allergic reactions: a feeling of heat, chills, nausea (symptoms usually go through 3-5 days).

Local reactions: sometimes phlebitis;
when extravasation - pain, irritation of surrounding tissues.
CONTRAINDICATIONS

- shock;

acute pancreatitis;

- hyperlipidemia;

- Lipoid nephrosis;

- Pregnancy;

- the period of lactation (breastfeeding);

- Hypersensitivity to the components of the drug.

PREGNANCY AND LACTATION

The drug is contraindicated for use in pregnancy and lactation (breastfeeding).

APPLICATION FOR FUNCTIONS OF THE LIVER

Contraindicated use of the drug in lipid nephrosis.

SPECIAL INSTRUCTIONS

When there are severe allergic reactions, the drug should be discontinued and symptomatic therapy should be prescribed.

When symptoms of phlebitis appear, it is recommended to administer 50-100 ml of a 0.9% solution of sodium chloride or a 5% solution of dextrose before or after iv administration of KLT.

Avoid extravasation of the drug.
To reduce the local irritant effect, the preparation, in case of its cooling, is recommended to be heated in a water bath to a temperature of 30 ° C.
With the separation of the emulsion, the drug can not be used.

OVERDOSE

In case of an overdose, there is usually no increase in side effects.

DRUG INTERACTION

Pharmaceutical interaction

KLT can not be mixed with other drugs.

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored in a place protected from light, inaccessible to children, at a temperature of no higher than 25 ° C;
Do not freeze. Shelf life - 1 year.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!